NCT06310876View on ClinicalTrials.gov

A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

May 29, 2024

Study Completion Date

June 26, 2024

Conditions

Healthy

Interventions

DRUG

ABBV-CLS-7262

• single oral Dose 1

DRUG

ABBV-CLS-7262

• single oral Dose 2

DRUG

Placebo

• single oral dose

DRUG

Moxifloxacin 400mg

• single oral dose

Trial Locations (1)

60030

AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake

Sponsors

Lead Sponsor

Calico Life Sciences LLC

Collaborators (1)

All Listed Sponsors

collaborator

AbbVie

INDUSTRY

lead

Calico Life Sciences LLC

INDUSTRY